Current and historical daily PE Ratio for Lattice Biologics Ltd (
) from 1995 to Jun 11 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Lattice Biologics stock (TSXV:LBL.H) PE ratio as of Jun 11 2024 is 0.
More Details
Lattice Biologics Ltd (TSXV:LBL.H) PE Ratio (TTM) Chart
Lattice Biologics Ltd (TSXV:LBL.H) PE Ratio (TTM) Historical Data
View and export this data going back to 1995. Start your Free Trial
Total 1289
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Lattice Biologics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-11 | At Loss | 2024-04-09 | At Loss |
| 2024-06-10 | At Loss | 2024-04-08 | At Loss |
| 2024-06-07 | At Loss | 2024-04-05 | At Loss |
| 2024-06-06 | At Loss | 2024-04-04 | At Loss |
| 2024-06-05 | At Loss | 2024-04-03 | At Loss |
| 2024-06-04 | At Loss | 2024-04-02 | At Loss |
| 2024-06-03 | At Loss | 2024-04-01 | At Loss |
| 2024-05-31 | At Loss | 2024-03-29 | At Loss |
| 2024-05-30 | At Loss | 2024-03-28 | At Loss |
| 2024-05-29 | At Loss | 2024-03-27 | At Loss |
| 2024-05-28 | At Loss | 2024-03-26 | At Loss |
| 2024-05-27 | At Loss | 2024-03-25 | At Loss |
| 2024-05-24 | At Loss | 2024-03-22 | At Loss |
| 2024-05-23 | At Loss | 2024-03-21 | At Loss |
| 2024-05-22 | At Loss | 2024-03-20 | At Loss |
| 2024-05-21 | At Loss | 2024-03-19 | At Loss |
| 2024-05-20 | At Loss | 2024-03-18 | At Loss |
| 2024-05-17 | At Loss | 2024-03-15 | At Loss |
| 2024-05-16 | At Loss | 2024-03-14 | At Loss |
| 2024-05-15 | At Loss | 2024-03-13 | At Loss |
| 2024-05-14 | At Loss | 2024-03-12 | At Loss |
| 2024-05-13 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
Lattice Biologics Ltd (TSXV:LBL.H) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Lattice Biologics Ltd
NAICS : 621511
SIC : 8681
ISIN : CA5184101056
Description
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers